top of page

Synovathera

About Us

Track Record

 Team Launches

Our team has executed end-to-end launches across Rx, devices, diagnostics, digital health, and pharmacy in Canada.

  • Pharmaceuticals

    • Eusa Pharma launch into Canada for Oncology/Rare Disease full setup
    • Jazz Pharma, Canadian Entry, Launch and train new staff for Oncology

    • Recordati Pharma Canadian Entry Launch and commercial build for Rare Diseas

    • Takeda Launch Oncology Canadian Launch

  • 15 additional Rx launches spanning Oncology, Rare Disease (Orphan), Endocrine (e.g., Thyroid), plus an Adrenaline relaunch.

  • Multiple molecule introductions from Pfizer, Elvium Pharma and Boehringer Ingelheim

  • Diagnostics, Devices & Digital

    • Launched Omega Laboratories full diagnostic suite into Canada and full expansion

    • POCT diagnostics, medical devices, skin-care lines, and AI-enabled solutions.

  • Pharmacy & Generics

    • Community/specialty pharmacy channel activation and generics commercialization

    • Ophthalmology & Surgical

  • Experience in surgical/wound-closure supporting ophthalmic use cases.

  • AI SaMD, Digital Health Launch

Cases

Case Study 1
Launching a Rare Disease Company in Canada
 
Challenge:

 

A global pharma leader needed to launch a dormant rare disease treatment in Canada, which lacked any local medical or commercial infrastructure.

 

​Our Approach:

 

We built the entire Canadian operation from the ground up, establishing the medical affairs and patient support infrastructure, creating a market-access strategy, and executing a tailored commercial launch.

Result:
Canada became the company's top-performing global affiliate, leading to full local independence and contributing to a major strategic acquisition. This case highlights our ability to execute full-scale, go-to-market transformations in highly specialized therapeutic areas.

Case Study 2

​​

Scaling a Digital Health Platform for Acquisition

Challenge:

 

A continuing health education (CHE) platform struggled with physician skepticism and limited adoption, hindering its growth and exit potential.

​​

Our Approach:
We optimized the platform, curated high-value content from Key Opinion Leaders (KOLs), and executed targeted growth campaigns to build credibility and drive user adoption across hospitals and associations.

Result:
The platform achieved rapid user adoption and was successfully acquired by a major healthcare education provider, demonstrating its lasting value. This case shows our expertise in scaling digital health ventures for successful exits.

Case Study 3

​​

​​​Disrupting a 59-Year Diagnostic Laboratory Monopoly

From market challenger to national presence in 18 months

The Challenge


A U.S.-based diagnostics lab entered the Canadian market long dominated by a single player. Strategic Growth AI delivered a comprehensive market entry strategy that transformed industry skepticism into widespread adoption, establishing the lab as a credible, trusted alternative.

Roadblocks We Overcame:

  • Market Resistance: Clients were deeply tied to the incumbent provider

  • Logistics Complexity: Vast geography + limited couriers raised delivery costs

  • Regulatory Barriers: Provincial + federal compliance requirements

  • Operational Scaling: Fast onboarding without compromising quality

  • Credibility Gap: Breaking 59 years of institutional loyalty required flawless execution

 

Results Achieved:

  • 1,700+ client sites secured across Canada

  • Significant revenue growth via strategic partnerships

  • Market credibility as the first serious challenger in 6 decades

  • Operational scalability for long-term growth and excellence

  • Bottom Line: Our client became Canada's fastest-growing diagnostics company, proving that focused execution beats legacy dominance.

bottom of page